SAB Biotherapeutics (SABS) Competitors $1.37 -0.02 (-1.15%) Closing price 04/15/2025 03:57 PM EasternExtended Trading$1.38 +0.00 (+0.15%) As of 04/15/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock SABS vs. DOMH, BOLT, CRIS, MTEM, AMGN, GILD, VRTX, REGN, ALNY, and BIIBShould you be buying SAB Biotherapeutics stock or one of its competitors? The main competitors of SAB Biotherapeutics include Dominari (DOMH), Bolt Biotherapeutics (BOLT), Curis (CRIS), Molecular Templates (MTEM), Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Alnylam Pharmaceuticals (ALNY), and Biogen (BIIB). These companies are all part of the "biotechnology" industry. SAB Biotherapeutics vs. Dominari Bolt Biotherapeutics Curis Molecular Templates Amgen Gilead Sciences Vertex Pharmaceuticals Regeneron Pharmaceuticals Alnylam Pharmaceuticals Biogen SAB Biotherapeutics (NASDAQ:SABS) and Dominari (NASDAQ:DOMH) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings, analyst recommendations, media sentiment and community ranking. Does the media refer more to SABS or DOMH? In the previous week, Dominari had 1 more articles in the media than SAB Biotherapeutics. MarketBeat recorded 3 mentions for Dominari and 2 mentions for SAB Biotherapeutics. SAB Biotherapeutics' average media sentiment score of 1.43 beat Dominari's score of -0.03 indicating that SAB Biotherapeutics is being referred to more favorably in the media. Company Overall Sentiment SAB Biotherapeutics Positive Dominari Neutral Do insiders and institutionals hold more shares of SABS or DOMH? 7.8% of SAB Biotherapeutics shares are held by institutional investors. Comparatively, 42.5% of Dominari shares are held by institutional investors. 26.5% of SAB Biotherapeutics shares are held by company insiders. Comparatively, 33.0% of Dominari shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Is SABS or DOMH more profitable? Dominari has a net margin of -180.22% compared to SAB Biotherapeutics' net margin of -1,450.14%. Dominari's return on equity of -32.89% beat SAB Biotherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets SAB Biotherapeutics-1,450.14% -94.37% -67.26% Dominari -180.22%-32.89%-29.47% Which has better earnings & valuation, SABS or DOMH? Dominari has higher revenue and earnings than SAB Biotherapeutics. Dominari is trading at a lower price-to-earnings ratio than SAB Biotherapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSAB Biotherapeutics$2.24M5.70-$42.19M-$3.68-0.37Dominari$12.59M3.42-$22.88M-$3.87-1.02 Do analysts rate SABS or DOMH? SAB Biotherapeutics presently has a consensus price target of $11.40, suggesting a potential upside of 729.69%. Given SAB Biotherapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe SAB Biotherapeutics is more favorable than Dominari.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score SAB Biotherapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Dominari 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the MarketBeat Community believe in SABS or DOMH? SAB Biotherapeutics received 31 more outperform votes than Dominari when rated by MarketBeat users. CompanyUnderperformOutperformSAB BiotherapeuticsOutperform Votes3183.78% Underperform Votes616.22%DominariN/AN/A Which has more risk and volatility, SABS or DOMH? SAB Biotherapeutics has a beta of 0.52, meaning that its share price is 48% less volatile than the S&P 500. Comparatively, Dominari has a beta of 0.86, meaning that its share price is 14% less volatile than the S&P 500. SummaryDominari beats SAB Biotherapeutics on 9 of the 17 factors compared between the two stocks. Remove Ads Get SAB Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SABS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SABS vs. The Competition Export to ExcelMetricSAB BiotherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$12.76M$2.90B$5.33B$7.57BDividend YieldN/A1.91%5.11%4.32%P/E Ratio-0.3731.0021.6617.82Price / Sales5.70441.16373.3994.61Price / CashN/A168.6838.1534.64Price / Book0.223.476.474.00Net Income-$42.19M-$72.06M$3.20B$247.23M7 Day Performance11.26%3.17%2.86%1.45%1 Month Performance-14.66%-16.97%-8.56%-6.24%1 Year Performance-70.89%-29.07%10.58%0.60% SAB Biotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SABSSAB Biotherapeutics3.5253 of 5 stars$1.37-1.2%$11.40+729.7%-68.5%$12.76M$2.24M-0.37140Short Interest ↓Positive NewsGap DownDOMHDominari0.5461 of 5 stars$3.56-1.9%N/A+34.8%$38.85M$12.59M-0.924Earnings ReportShort Interest ↑Gap DownBOLTBolt Biotherapeutics2.7108 of 5 stars$0.35-2.4%$1.13+220.2%-69.5%$13.80M$7.69M-0.2190Short Interest ↑Gap DownCRISCuris2.3742 of 5 stars$1.16-5.7%$21.00+1,710.3%-91.1%$9.85M$10.91M-0.1560Analyst ForecastHigh Trading VolumeMTEMMolecular TemplatesN/A$0.00-50.0%N/A-100.0%$1,000.00$23.48M0.00260Gap DownAMGNAmgen4.2708 of 5 stars$289.69-1.6%$314.04+8.4%+11.2%$155.62B$33.42B38.3728,000Analyst ForecastGILDGilead Sciences4.5435 of 5 stars$105.52-1.6%$105.12-0.4%+56.0%$133.54B$28.75B285.1917,000Positive NewsVRTXVertex Pharmaceuticals4.1 of 5 stars$474.560.0%$509.17+7.3%+26.0%$121.86B$11.02B-215.716,100Short Interest ↓Analyst RevisionPositive NewsHigh Trading VolumeREGNRegeneron Pharmaceuticals4.8717 of 5 stars$572.78-0.1%$966.88+68.8%-37.9%$62.62B$14.20B14.9611,900Analyst ForecastPositive NewsHigh Trading VolumeALNYAlnylam Pharmaceuticals4.5644 of 5 stars$232.95-1.2%$316.25+35.8%+56.4%$30.30B$2.25B-107.352,000BIIBBiogen4.698 of 5 stars$119.19-3.1%$213.33+79.0%-40.6%$17.45B$9.68B10.658,720Upcoming EarningsAnalyst Revision Remove Ads Related Companies and Tools Related Companies DOMH Competitors BOLT Competitors CRIS Competitors MTEM Competitors AMGN Competitors GILD Competitors VRTX Competitors REGN Competitors ALNY Competitors BIIB Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SABS) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersThe Crypto Market is About to Change LivesI've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredRadical shift coming to the stock market (read this ASAP)This is an urgent warning for all American investors … In a matter of days, we could see a radical shift in...Weiss Ratings | SponsoredFirst look: The $3,500 iPhoneDid you hear that just before Trump's tariffs took effect, Apple sent five cargo planes packed with MacBooks a...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SAB Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share SAB Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy SABS Stock Free SABS Stock Alerts